Tarran R, Grubb B R, Parsons D, Picher M, Hirsh A J, Davis C W, Boucher R C
Cystic Fibrosis/Pulmonary Research and Treatment Center, The University of North Carolina at Chapel Hill, 27599, USA.
Mol Cell. 2001 Jul;8(1):149-58. doi: 10.1016/s1097-2765(01)00286-6.
There is controversy over whether abnormalities in the salt concentration or volume of airway surface liquid (ASL) initiate cystic fibrosis (CF) airway disease. In vivo studies of CF mouse nasal epithelia revealed an increase in goblet cell number that was associated with decreased ASL volume rather than abnormal [Cl(-)]. Aerosolization of osmolytes in vivo failed to raise ASL volume. In vitro studies revealed that osmolytes and pharmacological agents were effective in producing isotonic volume responses in human airway epithelia but were typically short acting and less effective in CF cultures with prolonged volume hyperabsorption and mucus accumulation. These data show that (1) therapies can be designed to normalize ASL volume, without producing deleterious compositional changes in ASL, and (2) therapeutic efficacy will likely depend on development of long-acting pharmacologic agents and/or an increased efficiency of osmolyte delivery.
气道表面液体(ASL)的盐浓度或体积异常是否引发囊性纤维化(CF)气道疾病存在争议。对CF小鼠鼻上皮的体内研究显示,杯状细胞数量增加,这与ASL体积减少相关,而非[Cl(-)]异常。体内渗透质雾化未能提高ASL体积。体外研究表明,渗透质和药理剂在人气道上皮中能有效产生等渗体积反应,但通常作用时间短,在存在长期体积高吸收和黏液积聚的CF培养物中效果较差。这些数据表明:(1)可以设计疗法使ASL体积正常化,而不产生ASL有害的成分变化;(2)治疗效果可能取决于长效药剂的开发和/或渗透质递送效率的提高。